ArticleJournal of pancreatic cancer2020

Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors.

Mark H O'Hara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.